Progressive cone dystrophy

Progressive cone dystrophy (also known as cone degeneration or progressive cone degeneration) is a group of inherited retinal dystrophies characterized by the progressive loss of cone photoreceptor function in the retina. Cones are the photoreceptor cells responsible for central vision, color perception, and visual acuity in well-lit conditions. As cone cells progressively deteriorate, patients experience a gradual decline in these visual functions. The condition primarily affects the macula, the central part of the retina, while rod photoreceptors (responsible for peripheral and dim-light vision) are relatively preserved, at least in the earlier stages of the disease. Key clinical features include progressive loss of visual acuity, increasing sensitivity to bright light (photophobia), and impaired color vision (dyschromatopsia) that can progress to complete color blindness. Patients may also develop a central scotoma (a blind spot in the center of the visual field). Fundus examination may reveal macular atrophy, sometimes with a characteristic "bull's eye" maculopathy pattern. Electroretinography (ERG) typically shows significantly reduced or absent cone-mediated responses with relatively preserved rod responses, which is a hallmark diagnostic finding. The condition is bilateral and symmetric in most cases. Progressive cone dystrophy can be caused by mutations in numerous genes, including GUCA1A, GUCY2D, PDE6C, PDE6H, CNGA3, CNGB3, KCNV2, and others, with autosomal dominant, autosomal recessive, and X-linked inheritance patterns all described. The age of onset is variable but most commonly presents in childhood or early adulthood. There is currently no cure or disease-modifying treatment available. Management is supportive and includes the use of tinted lenses or filters to reduce photophobia, low-vision aids, and occupational therapy to help patients adapt to progressive visual loss. Gene therapy approaches are under active investigation for some genetic subtypes, offering hope for future targeted treatments.

Common questions about Progressive cone dystrophy